Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Lung Cancer Market Global Briefing 2017

Lung Cancer Market Global Briefing 2017

From $1,000.00

Including: Small Cell Lung Cancer, Mesothelioma And Carcinoid Tumors, Biologics And Small Molecules.
Covering: F. Hoffmann-La Roche, Astra Zeneca, Eli Lilly, Sanofi, Pfizer Inc.


Clear selection
SKU: 2251. Category: .
Description

Lung cancer Market Global Briefing 2017 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global lung cancer market.

Reasons to Purchase

• Get up to date information available on the lung cancer market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 2-3 working days of order.

Description

The Lung cancer Market Global Briefing Report from The Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The lung cancer market is one of the segments in the oncology drugs market, within the pharmaceutical drugs market.

The market characteristics section of the report defines and explains the market.

The market size section gives the lung cancer market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the lung cancer market and suggests approaches.

Scope

Markets Covered: Small Cell Lung Cancer, Mesothelioma and Carcinoid Tumors, Biologics and Small Molecules.

Companies Mentioned: F. Hoffmann-La Roche, Astra Zeneca, Eli Lilly, Sanofi, Pfizer Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Market value in $ billions.

Data segmentations: Regional breakdowns, market share of competitors, key sub segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Related Reports:

Pancreatic cancer Market Global Briefing 2017
Breast cancer Market Global Briefing 2017
Prostate cancer Market Global Briefing 2017
Ovarian cancer Market Global Briefing 2017
Gastric Cancer Market Global Briefing 2017
Non-Small Cell Lung Cancer Market Global Briefing 2017
Brain Tumor Market Global Briefing 2017
Colorectal Cancer Market Global Briefing 2017
Thyroid cancer Market Global Briefing 2017
Bladder Cancer Market Global Briefing 2017
Kidney Cancer Market Global Briefing 2017
Skin cancer Market Global Briefing 2017
Cervical Cancer Market Global Briefing 2017
Blood cancer Market Global Briefing 2017

Table Of Contents
1. Introduction
2. Lung cancer Market Characteristics
3. Lung cancer Market Historic Growth
• Drivers Of The Market
• Restraints On The Market
4. Lung cancer Market Forecast Growth
• Drivers Of The Market
• Restraints On The Market
5. Lung cancer Market Geography Split
6. Lung cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
7. Lung cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
8. Lung cancer Market Segmentation
9. Lung cancer Competitive Landscape
F. Hoffmann-La Roche
Astra Zeneca
Eli Lilly
Sanofi
Pfizer Inc.
10. Key Mergers And Acquisitions In The Lung cancer Market
11. Lung cancer Market Trends And Strategies
Appendix
NAICS Definitions of Industry Covered In This Report
Research Methodology
Methodology
Data
Market Numbers
Competitor Market Share Data
Analysis
Verification Through Expert Interviews
Referencing
Note on Currency Conversions
Abbreviations
Currencies
Research Inquiries
The Business Research Company List Of Tables
Table 1: Global Lung cancer Market Historic Market Size, 2012 – 2016, $ Billion
Table 2: Global Lung cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Table 3: Global Lung cancer Market, Split By Region, 2016, $ Billion
Table 4: Lung cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Table 5: Lung cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
Table 6: Global Lung cancer Market, Key Competitor Shares, 2016, Percentage (%)
Table 7: Global Lung cancer Market, Split By Segments, 2016, $ Billion List Of Figures
Figure 1: Global Lung cancer Market Historic Market Size, 2012 – 2016, $ Billion
Figure 2: Global Lung cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Figure 3: Global Lung cancer Market, Split By Region, 2016, $ Billion
Figure 4: Lung cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Figure 5: Lung cancer Market As A Proportion of Oncology Drugs Market, 2020, By Country
Figure 6: Global Lung cancer Market, Key Competitor Shares, 2016, Percentage (%)
Figure 7: Global Lung cancer Market, Split By Segments, 2016, $ Billion
Executive Summary
The lung cancer drugs market covers the drugs used in the treatment of lung cancer. These conditions include small cell lung cancer; mesothelioma; and carcinoid tumors. Based on the Segmentation by type of molecule, the market is segmented into two segments: biologics and small molecules. Some of the major drugs in this market are Hycamtin, Taxotere, Gemzar, Alimta, Iressa, Avastin, and Tarceva. The global lung cancer market was estimated to be around $11 billion as of 2016. The global lung cancer made up around 9% of the overall oncology drugs market in 2016. The lung cancer market was the fourth largest market in the global oncology drugs market in 2016. MicroRNA Application In Diagnosis and Treatment Of Lung Cancer Application of microRNA as biomarkers for the early detection and treatment of lung cancer is an emerging trend in this market. According to NCBI, increasing usage of miRNA-based markers provide opportunities for molecular diagnostics of lung cancer. miRNAs circulate the affected lung cancer cells and are also used in lung cancer classification, prognostic stratification, and drug-response prediction. Product Approval Regulatory approval for lung cancer drugs from FDA in the US and EMA in Europe is an emerging trend in this market. For instance, in June 2016, Genentech (a subsidiary of Roche) received FDA approval for its Alecensa (alectinib) drug that is used in the treatment of ALK-positive non small cell lung cancer.
Get Customized Report
Please fill in your details. Our team will get back to you